Indivior Pharmaceuticals (INDV) Long-Term Deferred Tax (2021 - 2026)

Indivior Pharmaceuticals' Long-Term Deferred Tax history runs 6 years deep, the most recent figure standing at $296.0 million for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax rose 6.09% year-over-year to $296.0 million; the TTM figure through Mar 2026 stood at $296.0 million (up 6.09% YoY), while the FY2025 annual figure was $323.0 million, up 16.61% from the prior year.
• Long-Term Deferred Tax was $296.0 million for Q1 2026 at Indivior Pharmaceuticals, down from $323.0 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $323.0 million in Q4 2025 to a low of $219.0 million in Q4 2022.
• Historically, Long-Term Deferred Tax has averaged $279.4 million across 5 years, with a median of $282.0 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Long-Term Deferred Tax surged 108.57% in 2022, then fell 3.15% in 2024.
• A 5-year view of Long-Term Deferred Tax shows it stood at $219.0 million in 2022, then jumped by 30.59% to $286.0 million in 2023, then fell by 3.15% to $277.0 million in 2024, then climbed by 16.61% to $323.0 million in 2025, then retreated by 8.36% to $296.0 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $296.0 million (Q1 2026), $323.0 million (Q4 2025), and $285.0 million (Q3 2025), per Business Quant data.